Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGIO-3 open-label extension of Cobenfy for agitation associated with Alzheimer's disease
MOH_2025-10-20_014391Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trospium and xanomeline in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Primary endpoint: Long-term safety and tolerability. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
trospiumxanomeline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on MOH_2025-10-20_014391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-20_014391.